Repositioning Candidate Details
| Candidate ID: | R0374 |
| Source ID: | DB01296 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Glucosamine |
| Synonyms: | |
| Molecular Formula: | C6H13NO5 |
| SMILES: | N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O |
| Structure: |
|
| DrugBank Description: | Glucosamine is commonly used as a treatment for osteoarthritis, although its acceptance as a medical therapy varies. It is an amino sugar and precursor of glycosylated proteins and lipids. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis. |
| CAS Number: | 3416-24-8 |
| Molecular Weight: | 179.1711 |
| DrugBank Indication: | Glucosamine is usually used in the treatment of osteoarthritis, although its efficacy is still in question. |
| DrugBank Pharmacology: | Osteoarthritis is characterized by the progressive degeneration of cartilage glycosaminoglycans. The formation of glucosamine is the rate limiting step in glycosaminoglycans synthesis thus the addition is glucosamine, would in theory provide a building block towards the synthesis of glycosaminoglycans and thus slow down the progression of osteoarthritis. Thus far however, the results have not been conclusive. |
| DrugBank MoA: | Glucosamine is a precursor of glycosylated proteins and lipids. Oral glucosamine is commonly used for the treatment of osteoarthritis. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis. Its use as a therapy for osteoarthritis appears safe, but there is conflicting evidence as to its effectiveness with more recent studies showing limited to no clinical benefit of use. Glucosamine is not FDA approved for use in humans. Since glucosamine is classified as a dietary supplement, safety and formulation are solely the responsibility of the manufacturer; evidence of safety and efficacy is not required as long as it is not advertised as a treatment for a medical condition. |
| Targets: | Interferon gamma; Transcription factor p65 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|